Comparative study of dacryocystorhinostomy with and without intraoperative application of Mitomycin C

Qadir, Maniah; Ahangar, Andleeb; Dar, Mohamed Ahsan; Hamid, Sumaya; Keng, Manzoor Qadir

doi:10.1016/j.sjopt.2013.09.005

Cited by 12 publications

(16 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of the included studies, the number of patients submitted to Ex-DCR was slightly lower than that submitted to En-DCR. However, the number of subjects who received MMC in Ex-DCR (14 studies) [6,8,11,[22][23][24][25][26][27][28][29][30][31][32], as well as in En-DCR (13 studies) [4,12,21,[33][34][35][36][37][38][39][40][41][42], was similar in both techniques. The clinical heterogeneity is considered the major disadvantage of all the clinical studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intra-Operative Mitomycin-C as Adjuvant Therapy in External and Endonasal Dacryocystorhinostomy: Systematic Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

Purpose: To evaluate the effect of mitomycin-C (MMC) on the success of external (Ex-DCR) or endoscopic dacryocystorhinostomy (En-DCR). Method: A systematic review of randomized clinical trials of Ex-or En-DCR with and without the use of MMC to treat primary acquired nasolacrimal duct obstruction (NLDO) was done. Two authors independently searched six databases from 1990 to 2019, using the terms ''dacryocystorhinostomy'' and ''mitomycin-C.'' Statistical and meta-analyses were performed using RevMan 5.3 software. Results: Twenty-seven studies involving 2158 surgeries were included in this systematic review. The Ex-DCR group comprised 14 studies [odds ratio (OR): 2.74; 95% confidence intervals (CI) 1.54-4.87; I 2 = 30%], while the En-DCR group 13 studies (OR: 1.69; 95% CI 1.21-2.37; I 2 = 0%). The use of MMC slightly increased the success rate of Ex-or En-DCR (OR: 2.1; 95% CI 1.52-2.9; I 2 = 14%). Conclusion: The intraoperative use of MMC is safe and slightly improves the success rate of Exor En-DCR. However, the evidence was very weak.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Studies have demonstrated larger osteotomy size in DCR surgery with intraoperative MMC application as adjuvant treatment [8,10]. However, according to others, adjuvant use of MMC to prevent failure in Ex-DCR or En-DCR is innocuous and does not change the chance of success of the DCR procedure [3,11,12].…”

Section: Introductionmentioning

confidence: 99%

Intra-Operative Mitomycin-C as Adjuvant Therapy in External and Endonasal Dacryocystorhinostomy: Systematic Review and Meta-Analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the study conducted by Maniah Quadir, Andleeb Ahangar and colleagues, 13 4 cases (16%) had high tear meniscus height at the end of 6 months compared to 2 cases (13.3%) of our control group. In the MMC group they found 1 eye (4%) with high tear meniscus height, whereas none of our patients in MMC group had a high tear meniscus height postoperatively.…”

Section: Discussionmentioning

confidence: 59%

“…Thus, this finding is an indicator of efficacy of Mitomycin C in preventing DCR stoma stenosis, even though our sample size was smaller. A similar comparative study of DCR with and without application of Mitomycin C was conducted by Maniah Quadir et al 13 in 50 patients of primary nasolacrimal duct obstruction, 51 in which 0.2 mg/mL of MMC was applied over the stoma for 5 minutes. They followed up the patients on 1st day, 1 st , 3 rd , 6 th weeks, 3 rd and 6 th months.…”

Section: Discussionmentioning

confidence: 90%

Endoscopic Dacryocystorhinostomy With or Without Intraoperative Application of Mitomycin C- A Comparative Study

Anisseril¹,

Reghunathan²,

Edacheriyan³

et al. 2017

jemds

View full text Add to dashboard Cite

BACKGROUNDEndoscopic Dacryocystorhinostomy (DCR) is one of the increasingly recognised surgeries performed by an Otorhinolaryngologist in the recent years. It is the surgery of choice for post saccular lacrimal obstruction. The most common cause of failure of dacryocystorhinostomy is secondary to reclosure of stoma due to scarring, adhesion and granulation tissue formation. Several modifications have been put forward by various authors in order to shorten operative time, reduce complications and to improve overall success rate of this surgery.The aim of this study is to study the efficacy and safety of intraoperative use of Mitomycin C in endoscopic dacryocystorhinostomy. MATERIALS AND METHODSStudy Design-Randomised controlled trial. This study was conducted in Department of Otolaryngology and Head and Neck Surgery, Academy of Medical Sciences, Pariyaram, Kerala, India. A total of 30 patients who underwent Endoscopic Dacryocystorhinostomy for post saccular lacrimal obstruction during the period of 15 months from June 2014 to August 2015 were included in the study. On the basis of randomisation technique by using lottery method, patients were assigned to two groups of 15 each; the Mitomycin C (MMC) group in which we used topical Mitomycin C (0.5 mg/mL) and the Control group without using Mitomycin C. Each patient was followed up with lacrimal syringing, tear meniscus height (TMH) assessment and endoscopic inspection of DCR stoma. The complications and the surgical outcomes were compared between the two groups. RESULTSA total of 30 Endoscopic Dacryocystorhinostomy was performed. At the end of 6 months followup period, 100% of patients in MMC group were asymptomatic when compared to 86.67% patients in the control group. The complications observed in the control group were granulation at the stomal site and synechiae formation. CONCLUSIONFrom the present study, we conclude that use of intraoperative Mitomycin C application over the DCR stomal edges can be recommended as a safe and effective method of prevention of postoperative stomal stenosis. KEYWORDS

show abstract

“…Период наблюдения за паци-ентами после операции также был различным и составлял от 6 до 12 мес [17,18]. Результативность в группе пациен-тов с использованием митомицина-С, по данным различ-ных авторов, составляла от 80 до 95,5% случаев [19][20][21].…”

unclassified

Therapeutic methods of scar prevention at the site of endonasal dacryocystorhinostomy

Atkova

Root

2015

Vestn. oftal'mol.

View full text Add to dashboard Cite

Comparative study of dacryocystorhinostomy with and without intraoperative application of Mitomycin C

Abstract: Although the difference between the two groups was not statistically significant, a distinctly higher success was achieved in patients undergoing dacryocystorhinostomy with intra operative Mitomycin C as compared to conventional dacryocystorhinostomy.

Cited by 12 publications

References 6 publications

Intra-Operative Mitomycin-C as Adjuvant Therapy in External and Endonasal Dacryocystorhinostomy: Systematic Review and Meta-Analysis

Intra-Operative Mitomycin-C as Adjuvant Therapy in External and Endonasal Dacryocystorhinostomy: Systematic Review and Meta-Analysis

Endoscopic Dacryocystorhinostomy With or Without Intraoperative Application of Mitomycin C- A Comparative Study

Therapeutic methods of scar prevention at the site of endonasal dacryocystorhinostomy

Contact Info

Product

Resources

About